A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, aged 7 to 17 years, who fulfill Rome III Criteria for Child/Adolescent Irritable Bowel Syndrome and have symptoms of constipation (IBS-C)
Linaclotide study for children with Irritable Bowel Syndrome- Constipation (IBS-C)
Sponsor: Allergan-Forest Research Institute
Enrolling: Male and Female Patients
Study Length: 12 Weeks
Clinic Visits: 6
IRB Number: AAAQ8246
U.S. Govt. ID: NCT02559817
Contact: Kelly Naranjo: 212-342-4414 / kvn2111@cumc.columbia.edu
Additional Study Information: We are currently recruiting pediatric patients ages 7-17 who suffer from Irritable Bowel Syndrome with Constipation (IBS-C) for our Linaclotide clinical trial. Study will involve 6 visits and will last anywhere from 10-12 weeks after the patient qualifies.
This study is closed
Julie Khlevner, MD
Do You Qualify?
Is child between the ages of 7 -17? Yes No
Does child suffer from Irritable Bowel Syndrome with Constipation (IBS-C)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kelly Naranjo